Context: Longitudinal studies of bone mineral density (BMD) in HIV have reported conflicting results.
H uman immunodeficiency virus (HIV) infection has
been associated with low bone mineral density (BMD) in numerous cross-sectional studies. A meta-analysis of cross-sectional studies reported an odds ratio of 6.4 for reduced BMD and 3.7 for osteoporosis in HIV-infected patients compared with uninfected controls (1) . Subsequently, in a meta-analysis of 10 controlled cross-sectional studies, we reported that HIV-infected groups were on average 5.1 kg lighter than comparable, uninfected controls, a finding that largely explained the differences in BMD between the groups (2) . The remaining differences in weight-adjusted BMD between the groups were small (2-3%) and unlikely to be of clinical importance (2) .
Longitudinal studies of HIV-infected cohorts have produced conflicting results with many studies reporting stable or increasing BMD over time (3) (4) (5) (6) , whereas other studies report substantial, short-term losses in BMD (7, 8) . Previously, we hypothesized that changes in body weight would also have an impact upon longitudinal studies of BMD in HIV (2, 6) . Weight loss occurs with advancing untreated HIV infection, but there is steady regain of weight after the commencement of highly active antiretroviral therapy (HAART) (9). Weight is a major determinant of BMD, and changes in weight positively correlate with changes in BMD (10 -12). Therefore, it would be predicted that BMD would decrease with advancing untreated HIV infection and increase after the commencement of HAART, with time lags between initiation of HAART, regain of body weight, and regain of BMD (6). Thus, it would be expected that longitudinal studies of HAART-untreated/naive cohorts would report decreasing BMD, whereas studies in HAART-treated patients would report stable or increasing BMD. 
Materials and Methods

Study selection
The meta-analysis was carried out according to the PRISMA Guidelines. MEDLINE, EMBASE, and the Web of Science were 
Eligibility criteria
A study was eligible for inclusion if it was published in English, reported data from adult participants (Ͼ18 yr), had a control group without HIV infection comparable for mean age (within 5 yr) or gender (male to female ratio within 15%), and had BMD data (or the change in BMD) reported at least 48 wk apart. Randomized controlled studies with groups assigned to agents that did not have an impact upon BMD or assigned to placebo that otherwise met these criteria were eligible for inclusion. Studies were excluded if BMD measurements were performed on different machines during the course of the study, unless validated conversion equations were used, if no measure of BMD spread was reported, or if bone mineral content only was reported. Studies that otherwise met the inclusion criteria but did not have a comparable control group without HIV infection were analyzed separately in secondary analyses. Where studies presented BMD T scores only, these were converted to absolute BMD where possible using manufacturer-supplied reference data. Where the same cohort was described in more than one publication, only the largest study conforming to the inclusion and exclusion criteria was included. Each of the potentially eligible studies was independently assessed by two of the authors (M.J.B. and T.K.M.W.), and a consensus was reached regarding the suitability of each study without knowledge of the BMD data.
Data extraction
Data were independently extracted from manuscripts by two authors (M.J.B. and T.K.M.W.) and any discrepancies resolved by consensus. Where studies reported data on subgroups receiving differing HIV treatment regimens, the data for the subgroups were pooled. Nonparametric summary data (median, interquartile range, and range) were converted to the mean and SD using published formulae (13). When BMD values were not presented in the manuscript text, electronic calipers were used to extract the data from figures.
Statistics
The primary endpoint was the difference in the percent change in BMD from baseline in the HIV group compared with the control group. Secondary analyses were the percent change from baseline and annualized rate of change at 1, 2, and 2.5 yr or later in the studies without a control group and in the HIV groups from the controlled studies. Studies reporting data at between 48 wk to 1.4 yr were pooled at the 1-yr time point, and studies from 1.5-2.4 yr at the 2-yr time point. All studies that reported data at the 1-and 2-yr time points were included in the analyses for these time points regardless of duration of followup. Where data on percent change from baseline were not reported, these data were calculated from the baseline and follow-up mean and SD (14).
Because of expected heterogeneity, we prespecified use of random-effects models to pool data (I 2 Ͼ 50% was considered significant heterogeneity). Funnel plots were inspected and were supplemented by calculation of the Egger statistic to check each analysis for publication bias. No consistent evidence of publication bias was present for any analysis (data not shown). All tests were two-tailed, and P Ͻ 0.05 was considered statistically significant. Data were analyzed using Comprehensive Metaanalysis version 2 (Biostat, Englewood, NJ).
Results
Supplemental Fig. 1 (published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org) shows the results of the search: 183 potentially relevant reports were identified, from which six studies with a comparable uninfected control group (6, 15-19) and 31 studies without a comparable uninfected control group (4, 7, 8, 20 -47) were eligible for inclusion in the analyses. Table 1 shows the baseline characteristics of the six controlled and 31 uncontrolled studies that collectively involved 779 and 2026 HIV-infected participants, respectively.
Controlled studies
The duration of follow-up in the six controlled studies ranged from 1.5-2.7 yr. Three studies were in premenopausal women (15, 16, 19), one in postmenopausal women (17), and two in men (6, 18). In all six studies, the majority of participants were taking HAART at baseline, although the exact proportion was not stated in three studies (16 -18). Five of the studies reported data only from individuals with follow-up data available, and one study (15) reported data on all participants but had a 75% dropout rate at 2 yr (Table 1 ). Figure 1 shows that at 1.5-2.7 yr, there was no significant difference between the percent change from baseline in BMD at the total hip, or femoral neck in HIV-infected cohorts compared with controls. At the spine, there was a decrease of 0.6% in BMD in HIVinfected cohorts compared with controls. Only one study reported data on total body BMD, and in that study, the HIV group had a significantly greater increase in BMD at the total body than the controls (Fig. 1) . One study reported data at 1 yr (15), and in that study, the change in BMD from baseline at the spine was nonsignificantly higher in the HIV group (difference ϭ 1.0; 95% confidence interval ϭ Ϫ0.5-2.5; P ϭ 0.19). Figures 2 and 3 show the percent change from baseline in BMD at 1 and 2 yr in 37 studies (31 uncontrolled studies and the HIV cohorts from six controlled studies). There was significant heterogeneity present in all analyses when the data were pooled; however, the heterogeneity was markedly reduced by stratifying the analysis by HAART status at baseline. Cohorts of men or premenopausal women in which the majority of participants were HAART treated at baseline had stable or increasing BMD at 1 yr (range, 0.2-1.1% increase from baseline) and at 2 yr had stable or slight decreases in BMD (range, 0.5% decrease from baseline to 0.1% increase from baseline). Only one study reported data from postmenopausal women (17). In this study, the changes from baseline were similar to expected changes and did not differ from the comparable uninfected control group at the spine and femoral neck, but decreases from baseline were greater than controls at the total hip (17). In contrast to the studies of participants treated with HAART at baseline, cohorts in which the majority of participants were HAART-naive/ untreated at baseline had significant loss of BMD ranging from 2.1-3.2% at 1 yr and 2.4 -4.4% at 2 yr. Figure 4 shows the annualized percent change in BMD from baseline in studies with follow up of at least 2.5 yr. There are few data available, but there is no consistent evidence of accelerated BMD loss in cohorts treated with HAART at baseline. There were small increases in the rate of BMD loss in the two studies of HAART-naive cohorts.
Uncontrolled studies
The annualized percent change in BMD at each site and each time point is summarized in Table 2 . In cohorts
FIG. 2.
Percent change from baseline in BMD at the lumbar spine, total hip, femoral neck, and total body at 1 yr. All cohorts are of men or premenopausal women, for whom the expected change in BMD is approximately 0%/yr. Four studies reported BMD data for regional sites derived from the total body scans (4, 22, 27, 28). treated with HAART at baseline, the annualized change in BMD remains stable over time with no evidence of accelerated loss. However, in cohorts that are HAART-naive/ untreated, there is early accelerated loss of BMD at 1 yr. This increased rate of BMD loss does not persist and is followed by longer periods of BMD stability or increases.
There were only three studies that included a group or subgroup treated with a HAART regimen that included tenofovir. In a study of 24 people followed for 1 yr, participants were treated with HAART at baseline and had a change in BMD from baseline of 0% at the spine and Ϫ3.3% at the total hip (45) . In a study of 180 people followed for 1 yr, participants were HAART-naive at baseline and had a change in BMD from baseline of Ϫ3.6% at the spine and Ϫ2.4% at the total hip (46) . In a study of 86 people followed for 5.5 yr, participants were HAART-naive at baseline and had a change in BMD from baseline at 1, 2, and 5.5 yr, respectively of Ϫ3.3, Ϫ2.3, and Ϫ1.7% at the spine and Ϫ3.2, Ϫ2.8, and Ϫ3.3% at the total hip (31).
Discussion
There was no consistent evidence of accelerated BMD loss over 1.5-2.7 yr in six studies that included an HIV-infected group, the majority of whom were HAART treated at baseline, and a comparable uninfected control group. In 37 longitudinal studies of HIV-infected cohorts, BMD changes over time were heterogeneous. In groups in which the majority of participants were treated with HAART at baseline, BMD was stable at 1-, 2-, and 2.5-yr and later time points, whereas there were decreases in BMD at all these time points in groups in which the majority of participants were HAART-naive/untreated at baseline. The annualized BMD loss in groups that were HAART-naive/ untreated at baseline was greatest at the 1-yr time point, and thereafter, longer periods of BMD stability or increases led to decreases in the annualized change in BMD.
Our analyses suggest that discrepancies between the results of previous longitudinal studies can be largely explained by HAART status at baseline. In HIV groups treated with HAART at baseline, changes in BMD did not differ from uninfected controls at the femoral neck or total hip. At the lumbar spine, there was a decrease in BMD compared with controls. However, the rate of BMD loss was small, approximately 0.25-0.3%/yr, and unlikely to be of clinical significance because it would require about 30 -40 yr of this rate of BMD loss to produce a 10% decrease in BMD relative to controls, equivalent to a change of 1 SD in the population BMD. In the 37 longitudinal studies, cohorts treated with HAART at baseline had stable or slightly increased BMD at 1 yr, stable or slightly decreased BMD at 2 yr, and stable BMD at 2.5 yr or later and had stable annualized changes in BMD. Taken together, these results suggest stable BMD in patients already established on HAART. In contrast, in the studies of HAART-naive/untreated participants at baseline, there was consistent evidence of accelerated bone loss at all sites and all time points. However, the annualized rate of bone loss was greatest at 1 yr, after which the rate of loss diminished due to longer periods of BMD stability or increases. These results are consistent with the previous report of Gallant and colleagues (5) who followed 600 HAART-naive individuals randomized to two different HAART regimens for 144 wk. When both groups are pooled, there was a 2.4% decrease in BMD at 48 wk at the spine and a 2.2% decrease at the hip. Subsequently, BMD increased by 0.9% at the spine and decreased by 0.3% at the hip over the next 96 wk (5). In a subgroup of 86 participants from this study, Cassetti and colleagues (31) reported an increase of 1.6% in BMD at the spine and a decrease of 0.1% at the hip between 48 wk and 5.5 yr. These reports and the findings of our meta-analysis suggest that initiation of HAART is associated with a short period of accelerated bone loss, followed by a longer period of increasing or stable BMD. These changes in BMD over time can potentially be explained by changes in body weight. Weight is a major determinant of BMD, and changes in weight are directly correlated with changes in BMD in various populations (10 -12). As weight decreases, BMD falls, with a lag time of several months between the weight loss and maximum decline in BMD (48) . Conversely, as weight increases, BMD rises, again with a similar lag time. With advancing untreated HIV infection, there is significant weight loss, but there is steady regain of this lost weight after the commencement of effective HAART. In our study of BMD in HIV-infected men, the average loss of body weight was 4 kg from time of HIV diagnosis until lowest body weight, which occurred 9 months after initiation of HAART (9). Thereafter, weight steadily increased by approximately 1 kg/yr, and the lost weight was regained after 4 yr of HAART (9). The loss of body weight during untreated HIV infection is likely to cause loss of BMD that persists into the early period after initiation of HAART, whereas gain in body weight after initiation of HAART eventually A number of other factors may contribute to the early accelerated BMD loss after initiation of HAART. HIV can infect osteoblasts, osteoclasts, and mesenchymal stem cells, directly or indirectly altering osteoblastogenesis and osteoclastogenesis (49) . Antiretroviral agents may also have direct effects on bone cells, or indirect effects via alterations in the receptor activator of nuclear factor ␤ pathway, cytokine production, mitochondrial function, phosphate metabolism, and vitamin D metabolism (49) . However, the effects of antiretroviral agents on BMD in longitudinal clinical studies are not consistent. Initiation of HAART regimens containing tenofovir have been reported to cause greater short-term bone loss (about 1-1.5% at 1 yr) compared with other regimens (5, 46), although these differences subsequently diminished or stabilized (5, 31). Tenofovir can also cause urinary phosphate wasting leading to hypophosphatemia and osteomalacia (50) , although this adverse effect was not reported in clinical trials (5, 31). Results of studies comparing groups randomized to different HAART regimens (5, 8, 30, 37, 39, 44, 46) or switched from one regimen to another (33, 36, 45) have been inconsistent, and no agents have been consistently associated with greater bone loss, except for tenofovir, as described previously. Furthermore, traditional risk factors for bone loss such as smoking, alcohol use, hypogonadism, and glucocorticoid use are more common in HIV-infected patients (49) . Some or all of these factors may contribute to the observed changes in BMD with HAART treatment, but it is difficult to explain the pattern of early accelerated BMD loss followed by BMD stability/increases when exposure to the putative factors (HIV infection, HAART, and traditional risk factors) persists during the period of observation in the longitudinal studies.
A recent randomized trial reported greater bone loss with continuous compared with intermittent antiretroviral treatment (51) . At the spine, BMD loss was greater in the continuous group at 1 yr but not at 2-4 yr, whereas at the total hip, BMD loss was greater in the continuous group at 1-2 yr but not at 3-4 yr. However, these results should be interpreted with caution for several reasons: there was no control group without HIV; it was an openlabel study that was terminated early with results presented for only a subgroup of randomized patients, and there were differences between the groups at baseline in factors known to influence bone loss such as gender, race, and antiretroviral use; no analyses by HAART status at baseline were reported; and rates of bone loss in the continuous group were much higher at the hip than in other studies of cohorts established on HAART in our review.
The relationship between HIV infection and fracture incidence is unclear. Several cohort studies have reported no increase in fracture rates in HIV-infected patients compared with controls in unadjusted analyses (52) (53) (54) or analyses adjusted for baseline differences (55) . Other investigators have assessed fracture rates using registries to form large cohorts. Triant and colleagues (56) reported fracture prevalence by HIV status in more than 2 million individuals who had at least one inpatient or outpatient assessment over a 12-yr period. Fracture prevalence was higher in HIV-infected individuals, but no adjustment for differences in risk factors between groups occurred, the mode of fracture was not reported, and the timing of fractures in relation to diagnosis of HIV was not reported. Womack and colleagues (57) reported that HIV status was not related to fracture incidence in more than 100,000 male veterans after adjustment for comorbidities. Thus, currently, there is no clear evidence of increased fragility fractures in HIV when established risk factors for fracture are controlled for. Any increased risk of fractures in HIV may result from an increased prevalence of traditional risk factors for fracture such as low body weight, smoking, and alcohol use. Whether these same findings will apply to older cohorts of HIV-infected people, who are at highest risk of fragility fractures, is unknown but an important question to be addressed.
There are limitations to our analyses. There were relatively few studies with control groups that met the criteria for inclusion in our review, although we also included uncontrolled studies where possible. Publication bias may have influenced our findings, although we did not find consistent evidence of this. If such a bias was present, it is likely to favor publication of studies reporting lower BMD or accelerated loss of BMD in HIV-infected populations. Most studies of the skeletal effects of HIV have been carried out in younger individuals. Further studies in older men and postmenopausal women are required to determine whether the same relationships between HIV and BMD or fracture observed in younger individuals are also observed in older populations at higher risk of fragility fractures. Finally, we were not able to assess whether individual components of HAART (including tenofovir) might have differential skeletal effects.
Taken together, our results suggest that low BMD should not be a concern for the majority of younger and middle-aged individuals with HIV, who are adequately treated with antiretroviral therapy and well nourished. Determining whether this also applies to older cohorts of HIV-infected people is an important question to be addressed. In existing studies, BMD in cohorts established on HAART remains stable over time, whereas cohorts initiating HAART have a short-term increase in loss of BMD followed by a longer-term period of BMD increase/stability. Thus, it may be justified to reconsider current recommendations for lifelong monitoring of BMD every 1-2 yr during antiretroviral therapy (7, 49, 58) . Decisions about investigating and treating low BMD in HIV-infected patients should be made using guidelines available for the general population (59, 60) , with particular focus on addressing modifiable risk factors for low BMD or fractures such as alcohol use, cigarette smoking, and low body weight. Effective antiretroviral treatment and avoidance of undernutrition remain the two most important factors in optimizing skeletal health in HIV-infected individuals.
